

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

**(1) CHANGE IN COMPOSITION OF AUDIT COMMITTEE,  
REMUNERATION COMMITTEE AND NOMINATION COMMITTEE;  
(2) ESTABLISHMENT OF STRATEGY COMMITTEE;  
AND  
(3) ESTABLISHMENT OF COMMERCIALIZATION COMMITTEE**

**CHANGE IN COMPOSITION OF AUDIT COMMITTEE, REMUNERATION  
COMMITTEE AND NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes to the composition of the audit committee of the Company (the “**Audit Committee**”), the remuneration committee of the Company (the “**Remuneration Committee**”) and the nomination committee of the Company (the “**Nomination Committee**”), with effect from December 15, 2025:

Mr. Chen Guoming, a non-executive Director and the chairman of the Board, has been appointed as a member of the Audit Committee, and ceased to be a member of the Remuneration Committee and the chairperson of the Nomination Committee.

Dr. Hu Bingshan, an independent non-executive Director, has been re-designated as the chairperson of the Nomination Committee, and appointed as a member of the Remuneration Committee, and ceased to be a member of the Audit Committee.

Dr. Brian Chang, a non-executive Director, has been appointed as a member of the Nomination Committee.

## ESTABLISHMENT OF STRATEGY COMMITTEE

The Board hereby announces that, with effect from December 15, 2025, the Board resolved to establish the strategy committee of the Board (the “**Strategy Committee**”). The establishment of the Strategy Committee aims to conduct researches and submit proposals regarding the long-term development strategies and major development decisions of the Company. The Strategy Committee consists of six members, including Dr. Brian Chang, Mr. Chen Guoming, Mr. Zhang Ruinian, Mr. Philippe Wanstok, Mr. Deng Aoyi and Dr. Hu Bingshan, and Dr. Brian Chang acts as the chairperson.

As at the date hereof, the Strategy Committee convened a meeting to conduct a comprehensive and prudent assessment of the technological reserves, R&D resources and collaborative potential of both structural heart business and cardiac rhythm management business. The Strategy Committee concluded that, leveraging the Group’s leading design capabilities in passive implants and transcatheter delivery systems, as well as deep expertise accumulated in hemodynamic platforms, together with the MicroPort Cardiac Rhythm Management Limited (微創心律管理有限公司)’s long-standing capabilities in active implant development and its core competencies in AI diagnostics, biological signal collection, algorithm development and big data platform, the Group will be well positioned not only to optimize its existing product pipeline but also to enter the heart failure treatment market after the completion of the proposed merger (the “**Merger**”) of the two businesses. Accordingly, the Strategy Committee has resolved to establish integrated heart failure management as one of the core strategic focuses of the Group after the completion of the Merger, with the ambition to become an emerging technology leader in the diagnosis and treatment of heart failure.

The Board endorses and supports the decisions of the Strategy Committee, believing that the anticipated synergies following the Merger will contribute to building a comprehensive heart failure management solution that covers all causes, all stages, and the entire course of the disease. This solution will provide complete heart failure management services across different etiologies, various disease stages, and the full “monitoring–diagnosis–treatment–management” continuum. It will also fully leverage the complementary strengths of the two business lines in device-based therapy and continuous monitoring, offering physicians and patients an innovative, full-course heart failure health management solution.

## ESTABLISHMENT OF COMMERCIALIZATION COMMITTEE

The Board hereby announces that, with effect from December 15, 2025, the Board resolved to establish the commercialization committee of the Board (the “**Commercialization Committee**”). The establishment of the Commercialization Committee aims to further optimize the planning and implementation of the Company’s commercialization system, and to fully leverage on the guidance of the Commercialization Committee, so as to enhance the competitiveness edges of the Company’s products in the market during commercialization. The Commercialization Committee consists of five members, including Mr. Chen Guoming, Dr. Brian Chang, Mr. Zhang Ruinian, Mr. Philippe Wanstok, and Ms. Wu Xia. Mr. Chen Guoming acts as the chairperson.

By Order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Chen Guoming**  
*Chairman*

Shanghai, PRC, December 15, 2025

*As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.*